Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology

Abstract:
- Most potent photodisinfection agent known today -

University College London and Ondine Biopharma Announce Breakthrough Staphyloccocal Photodisinfection Technology

LONDON, UK and VANCOUVER, Canada | Posted on October 9th, 2007

UCL Business PLC, and Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) today announced an important
advance in photo-disinfection technology used to kill staphylococci such as methicillin-resistant Staphylococcus aureus (MRSA). In a multi-year collaborative research effort, scientists developed a nanotechnology-based photosensitizer that dramatically enhanced antimicrobial lethality at very small unit doses. The results of the research were published in the Royal Society of Chemistry's Journal of Materials Chemistry, 2007, 17, 3739-3746 and, because of the importance of the advancement, this publication has been selected for inclusion in the Royal Society of Chemistry's journal Chemical Biology Research Articles.

"The new nanoparticle photosensitizer is the most potent light-activated
antimicrobial agent known to date," said Dr. Cale Street, Director of
Research, Ondine Biopharma. "By covalently attaching gold nanoclusters to an
existing photosensitizer, we were able to dramatically boost bacterial killing
efficacy. We can now use very low concentrations of photosensitizer to achieve
greater than 99.99% eradication of bacteria in seconds to minutes, improving
our ability to develop photodisinfection-based products for the clinical
treatment of infections in wounds, burns, and other conditions."

"This development is the culmination of an intensive, cross-functional
research effort to develop next-generation anti-MRSA photodisinfection
agents," said Professor Michael Wilson, Division of Microbial Diseases,
University College London. "As resistance to antibiotics continues to increase
in most of the major human pathogens, this powerful technology has great
potential in the struggle against the growing prevalence of hospital-acquired
infections."

Ondine Biopharma owns exclusive rights to worldwide patent applications
covering this photodisinfection technology. With widespread antimicrobial
indications including eradication of MRSA from the nose and other areas,
treatment of conditions such as periodontal diseases, otitis externa, nailbed
fungus and the disinfection of burns and wounds.

####

About CL Business PLC
UCL Business PLC (UCLB) is the organisation responsible for
commercializing research generated within University College London (UCL) and
associated organisations. It is primarily responsible for protecting
inventions and transacting commercial activity including options, licences and
collaborative commercial research associated with the University. UCLB also
has responsibility for creating and spinning-out companies from UCL. UCLB is
wholly-owned by UCL and operates as an independent company with its own Board
of Directors.

About Periowave(TM) and Photodisinfection

Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
photosensitive compounds to specifically target and destroy microbial
pathogens and reduce the symptoms of disease. The compounds are topically
applied and lasers of appropriate wavelength and intensity are used to
disinfect the treatment site. The Company's Periowave(TM) photodisinfection
system is currently approved in Canada for nasal eradication of pathogenic
bacteria such as MRSA and the oral treatment of periodontitis, gingivitis,
peri-implantitis, peri-mucositis, endodontics, and in the European Union for
nasal eradication of MRSA, adult periodontitis, endodontics and
peri-implantitis. The photodynamic disinfection technologies were developed by
Professor Michael Wilson and colleagues at the Eastman Dental Institute,
University College London, and licensed to Ondine by UCL Business PLC,
University College London. Full text of the research publication described
above can be found at J. Mater. Chem., 2007, 17, 3739-3746. Additional
information about Periowave(TM) is available at http://www.periowave.com .

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance. The Company is headquartered in Vancouver, British
Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and
an international office in St. Michael, Barbados. For additional information,
please visit the Company's website at: http://www.ondinebiopharma.com

Forward-Looking Statements:

Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.

For more information, please click here

Contacts:
Carolyn Cross
President and Chief Executive
Officer
Ondine Biopharma Corporation
(604) 669-0555


Christina Bessant
Investor Relations
The Equicom Group Inc.
(416) 815-0700 ext. 269


Irma Gomez-Dib
Media & Investors Relations
FD International
(212) 850-5761


Nominated Adviser
Neil Johnson/Ryan Gaffney
Canaccord Adams Ltd
+44(0)20 7050 6500

Copyright © CNW Group Ltd.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Novel Method to Determine Optical Purity of Drug Components March 1st, 2015

Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Announcements

Imec, Murata, and Huawei Introduce Breakthrough Solution for TX-to-RX Isolation in Reconfigurable, Multiband Front-End Modules for Mobile Phones: Electrical-Balance Duplexers Pave the Way to Integrated Solution for TX-to-RX Isolation March 1st, 2015

Imec Demonstrates Compact Wavelength-Division Multiplexing CMOS Silicon Photonics Transceiver March 1st, 2015

onic Present breakthrough in CMOS-based Transceivers for mm-Wave Radar Systems March 1st, 2015

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Patents/IP/Tech Transfer/Licensing

onic Present breakthrough in CMOS-based Transceivers for mm-Wave Radar Systems March 1st, 2015

New Paper-like Material Could Boost Electric Vehicle Batteries: Researchers create silicon nanofibers 100 times thinner than human hair for potential applications in batteries for electric cars and personal electronics February 20th, 2015

Nanotech Discoveries Move from Lab to Marketplace with Lintec Deal: Licensing Partnership Brings Together University Technology, New Richardson-Based Facility Directed by Alumni February 9th, 2015

Graphenea granted patent on graphene transfer February 9th, 2015

Research partnerships

Imec, Holst Centre and Renesas Present World’s Lowest Power 2.4GHz Radio Chip for Bluetooth Low Energy March 1st, 2015

Imec, Murata, and Huawei Introduce Breakthrough Solution for TX-to-RX Isolation in Reconfigurable, Multiband Front-End Modules for Mobile Phones: Electrical-Balance Duplexers Pave the Way to Integrated Solution for TX-to-RX Isolation March 1st, 2015

Imec Demonstrates Compact Wavelength-Division Multiplexing CMOS Silicon Photonics Transceiver March 1st, 2015

onic Present breakthrough in CMOS-based Transceivers for mm-Wave Radar Systems March 1st, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE